img
2022 ASH 重磅 | Late-Breaking Abstracts一览

一年一度的美国血液学会(ASH)年会是全球血液学领域规模最大、涵盖最全面的国际学术盛会之一。今年,第64届ASH年会将于12月10-13日在线下及线上召开,目前,万众瞩目的重磅研究Late-Breaking Abstracts(LBA)已经公布,其报告时间为美国中部时间2022年12月13日上午9:00-10:30,让我们先盘点一下吧。

摘要号:LBA-1

英文标题:

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial.

中文标题:

贝林妥欧单抗巩固治疗可改善可测量残留病灶阴性缓解的新诊断成人B-ALL患者的总体生存:来自ECOG-ACRIN E1910随机III期国家合作临床试验网络研究的结果。

报告人:

Mark R. Litzow

单位:

Division of Hematology, Mayo Clinic, Rochester, MN

摘要号:LBA-2

英文标题:

Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study.

中文标题:

口服Iptacopan(一种B因子近端补体抑制剂)单药治疗阵发性睡眠性血红蛋白尿和残留性贫血患者的疗效优于静脉末端补体抑制治疗标准Eculizumab或Ravulizumab,且安全性良好:来自随机、主动对照、开放标签、多中心、III期Apply-PNH研究的结果。

报告人:

Regis Peffault De Latour

单位:

French Référence Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France

摘要号:LBA-3

英文标题:

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43).

中文标题:

与大剂量化疗联合自体造血干细胞移植(HDC-ASCT)作为原发性中枢神经系统淋巴瘤患者巩固治疗相比,非清髓性化学免疫疗法对生存的影响——一项国际随机III期试验(MATRix/IELSG43)的结果。

报告人:

Gerald Illerhaus

单位:

Department of Hematology, Oncology Stem Cell Transplantation and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany

摘要号:LBA-4

英文标题:

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703.

中文标题:

移植后环磷酰胺、他克莫司和吗替麦考酚酯作为减低强度预处理中预防移植物抗宿主病(GVHD)的新标准:III期BMT CTN 1703研究的结果。

报告人:

Shernan G Holtan

单位:

University of Minnesota, Minneapolis, MN

摘要号:LBA-5

英文标题:

Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial.

中文标题:

低分子肝素与标准妊娠治疗用于复发性流产和遗传性血栓形成倾向女性的比较(ALIFE2):一项开放标签、III期随机对照试验。

报告人:

Saskia Middeldorp

单位:

Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands

摘要号:LBA-6

英文标题:

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study.

中文标题:

在复发/难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤(R/R CLL/SLL)的治疗中,泽布替尼显示出优于伊布替尼的无进展生存期(PFS):来自ALPINE随机III期研究的最终分析结果。

报告人:

Jennifer R. Brown

单位:

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA


上一篇:从“石头人”到“公主病”,你知道这7种“怪病”吗?
下一篇:张晓辉教授:中国造血干细胞移植前景和展望

关键词:
img

无极血康中医医院院长袁六妮

系中国民营医疗机构协会理事、石家庄市政协委员、石家庄市劳动模范,从事医疗工作40余年,继承和发扬中国传统医学文化,以血液病的临床研究为主题,汲取传统医学精华,在攻克治疗血液病方面取得了有效成果,积累了丰富 的经验。

相关文章推荐